KHPG
LIVE

Add to watchlist:

No watchlists yet
View on USPTO

KHPG Trademark

Serial Number: 79221610 • Registration: 5603711

KHPG is a trademark filed by Chengdu Kanghong Pharmaceuticals Group Co., Ltd. on September 13, 2017. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

Chengdu Kanghong Pharmaceuticals Group Co., Ltd. (7 trademarks)

No.36, Shuxi Rd.,
Sichuan , CN

Entity Type: 99

Trademark Details

Filing Date

September 13, 2017

Registration Date

November 13, 2018

Published for Opposition

August 28, 2018

Cancellation Date

May 30, 2025

Goods & Services

Medicines for humans for the treatment or prevention of dermatological, cardiovascular, hematological, bone, respiratory, central nervous system, endocrinological, circulatory, gastroenterological, stomach, digestive, hormonal, diabetic, muscular, rheumatic, immune system, ocular and metabolic diseases and disorders; medicines for humans to treat or prevent diabetes, coughs, colds, influenza, headaches and allergic reactions; anti-infectives; anti-inflammatories; vaccines; pharmaceutical preparations used for the relief of pain and to reduce fever; pharmaceutical preparations and substances for the prevention and/or treatment of cardiovascular diseases, hemophilia, metabolic diseases, cancer, multiple sclerosis, urologic diseases, sexual dysfunction, osteoporosis, and climacteric diseases; pharmaceutical preparations, namely, anticoagulants and platelet aggregation inhibitors; contraceptive preparations, analgesics, anti-pyretics, anti-inflammatory preparations, anti-septic preparations, medicated lip balm, anesthetic spray for topical use, astringents, pediculicides, decongestants, antifungal agents, anti-infective pharmaceutical preparations, antacids, cold preparations in the nature of preparations for treating colds, menstrual symptom treatment preparations and dermatologicals; vitamin and mineral supplements; calcium supplements; pharmaceutical preparations, namely, ophthalmics; pharmaceutical preparations for the treatment of ophthalmic diseases and conditions; crude drugs for the treatment of central nervous system diseases, namely, hypertension, hyperlipidemia, schizophrenia and melancholia, digestive system diseases, namely, dyspepsia, chronic gastritis, chronic lithogenous cholecystitis, chronic cholecystitis and gall-stone, ophthalmology system diseases, namely, wet Age-related Macular Degeneration (AMD), and other diseases, namely, fever, irritability, red eyes, mouth sores, sore throat, swollen gums, constipation, pharyngitis, tonsillitis, gingivitis, upper respiratory infection (URI), acute bronchitis, diabetes and nephropathy ; Chinese patent medicine for the treatment of central nervous system diseases, namely, hypertension, hyperlipidemia, schizophrenia and melancholia, digestive system diseases, namely, dyspepsia, chronic gastritis, chronic lithogenous cholecystitis, chronic cholecystitis and gall-stone, ophthalmology system diseases, namely, wet Age-related Macular Degeneration (AMD), and other diseases, namely, fever, irritability, red eyes, mouth sores, sore throat, swollen gums, constipation, pharyngitis, tonsillitis, gingivitis, upper respiratory infection (URI), acute bronchitis, diabetes and nephropathy ; biochemical medicines for the treatment of cancer; radioactive medicines for the treatment of cancer; gases for medical purposes; disinfectants; solutions for contact lenses; dietetic substances adapted for medical use; food for babies; depuratives; pesticides; disinfectant wipes impregnated with disinfecting compounds; medical wound dressings; teeth filling materials

Filing History

TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Jan 30, 2026 INTR
CANCELLED SECTION 71
May 30, 2025 C71T
NEW REPRESENTATIVE AT IB RECEIVED
Jun 9, 2024 NREP
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Nov 13, 2023 REM3
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Feb 10, 2022 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Feb 10, 2022 TCCA
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Feb 10, 2022 EWAF
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Feb 10, 2022 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Feb 10, 2022 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Feb 10, 2022 COAR
FINAL DECISION TRANSACTION PROCESSED BY IB
Apr 19, 2019 FINO
GENERIC MADRID TRANSACTION SENT TO IB
Feb 21, 2019 XXSS
GENERIC MADRID TRANSACTION CREATED
Feb 21, 2019 XXCR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Feb 13, 2019 FICR
REGISTERED-PRINCIPAL REGISTER
Nov 13, 2018 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 28, 2018 NPUB
PUBLISHED FOR OPPOSITION
Aug 28, 2018 PUBO
NOTIFICATION PROCESSED BY IB
Aug 24, 2018 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Aug 8, 2018 OPNS
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 8, 2018 NONP
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Aug 8, 2018 OP2R
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 18, 2018 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 18, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 18, 2018 CRFA
ASSIGNED TO LIE
Jul 17, 2018 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 5, 2018 TROA
REFUSAL PROCESSED BY IB
Jan 27, 2018 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jan 9, 2018 RFCS
REFUSAL PROCESSED BY MPU
Jan 9, 2018 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Dec 19, 2017 RFCR
NON-FINAL ACTION WRITTEN
Dec 18, 2017 CNRT
ASSIGNED TO EXAMINER
Dec 16, 2017 DOCK
APPLICATION FILING RECEIPT MAILED
Dec 12, 2017 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 7, 2017 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Nov 23, 2017 REPR